NEW! TOXOPLASMA IgG AVIDITY TEST

Dears,

We are pleased to inform you that Avicena Laboratory began to work a new analysis: 

 

TOXOPLASMA IgG AVIDITY TEST

 

* Method: Indirect chemiluminescent immunoassay (CLIA)

* About the test:

Toxoplasma gondii is an obligate intracellular protozoan parasite that is distributed worldwide. Human can acquire the infection by accidental ingestion of oocysts from cat feces, by ingestion of infected meat, in utero or by transfusion or transmission by organ transplant.

Women infected during the first trimester can have spontaneous abortion and hydrocephalus. Disease acquired later in pregnancy causes less severe illness.

IgM antibodies appear 5 days after infection and fall to low levels within weeks or months in the majority of patients.

IgG antibodies appear weeks after infection and persist for the rest of the life. 

Since IgM may persist for months, IgG avidity testing can be of aid for the serological diagnosis of primary infections. The avidity of IgG is low early in infection with the avidity of IgG antibodies increasing over time. Avidity reflects the aggregate strength with which polyclonal IgG binds to antigens measured by the effect that a chemical denaturant has onto that binding.

 

Interpretation of the result:

Result (Index)

Interpretation

< 0.4

Low avidity

0.4-0.5

Intermediate avidity

› 0.5

High avidity

 

Avidity indexes lower than 0.40 are more in favor of recent primo-infection of less than 4 months.

Avidity indexes between 0.40 and 0.50 do not enable to distinguish a recent infection from a former infection. For these samples, other markers and/or avidity determination methods or a new serum sample (collected 3 or 4 weeks later) should be used.

Avidity indexes higher or equal to 0.50 are more in favor of past-infection of more than 4 months.

 

* Price for the test: 950,00 MKD

* Required sample: serum or plasma

* Time to result: Within 24 hours

 

For any additional information or questions, feel free to contact us on our phones 02 / 3079-700

 

With respect,

 

PHI Avicena Laboratory